Shukla

SymphonyAI’s Head of AI/ML Pushpraj (Raj) Shukla Appointed CTO

Retrieved on: 
Tuesday, February 27, 2024

SymphonyAI , a leader in predictive and generative enterprise AI SaaS, announced today that Pushpraj (Raj) Shukla has been appointed as CTO .

Key Points: 
  • SymphonyAI , a leader in predictive and generative enterprise AI SaaS, announced today that Pushpraj (Raj) Shukla has been appointed as CTO .
  • Shukla’s team includes both AI researchers and engineers working on cutting-edge predictive and generative AI models and their application to high-value ‘vertical use cases’ in critical industry sectors.
  • His team will also oversee the tooling and enforcement of enterprise security, privacy, and responsible AI policies for SymphonyAI’s offerings.
  • The company also launched an Industrial LLM to support SymphonyAI and third-party applications for industrial monitoring and predictive maintenance.

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Retrieved on: 
Wednesday, June 14, 2023

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat “Sath” Shukla, Spero’s current Chief Financial Officer and Treasurer, will serve as Spero’s President and Chief Executive Officer (CEO), and as a member of the Board of Directors, effective August 1, 2023.

Key Points: 
  • Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023
    Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors
    CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat “Sath” Shukla, Spero’s current Chief Financial Officer and Treasurer, will serve as Spero’s President and Chief Executive Officer (CEO), and as a member of the Board of Directors, effective August 1, 2023.
  • Mr. Shukla will succeed Spero’s current CEO and President, Ankit Mahadevia, M.D., who will become Chairman of the Board of Directors, effective August 1, 2023.
  • “It has been an honor to lead Spero since its inception and I am thrilled to welcome Sath as our next CEO,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
  • Until this search is completed, the Board has appointed Stephen J. DiPalma as Interim CFO and Treasurer, effective August 1, 2023.

SymphonyAI Appoints Vice President of Artificial Intelligence and Machine Learning

Retrieved on: 
Tuesday, August 2, 2022

PALO ALTO, Calif., Aug. 2, 2022 /PRNewswire/ -- SymphonyAI, a leader in high-value enterprise AI SaaS for strategic industries, announced today that Pushpraj (Raj) Shukla has joined the company as vice president of artificial intelligence and machine learning (AI/ML) and head of incubation.

Key Points: 
  • PALO ALTO, Calif., Aug. 2, 2022 /PRNewswire/ -- SymphonyAI, a leader in high-value enterprise AI SaaS for strategic industries, announced today that Pushpraj (Raj) Shukla has joined the company as vice president of artificial intelligence and machine learning (AI/ML) and head of incubation.
  • Shukla will lead the advancement of the enterprise AI platform, Eureka, that supports SymphonyAI's applications in key vertical industries.
  • Shukla joins SymphonyAI from Microsoft, where he served as partner director of AI and ML for business applications and platforms.
  • SymphonyAI is a SAIGroup company, backed by a $1 billion commitment from successful entrepreneur and philanthropist Dr. Romesh Wadhwani.

ConverseNow Raises $15 Million To Drive Innovation At The Drive-Thru

Retrieved on: 
Thursday, July 29, 2021

AUSTIN, Texas, July 29, 2021 /PRNewswire-PRWeb/ -- ConverseNow, the leading voice-based AI technology for restaurants, has closed a $15 million Series A round led by Craft Ventures .

Key Points: 
  • AUSTIN, Texas, July 29, 2021 /PRNewswire-PRWeb/ -- ConverseNow, the leading voice-based AI technology for restaurants, has closed a $15 million Series A round led by Craft Ventures .
  • Moneta Ventures and angel investors Federico Castellucci and Ashish Gupta also participated, bringing the total funding to $18.3 million.
  • Its cloud-based, multilingual solution personalizes restaurant orders in high-volume voice channels such as phone, drive-thru, self-service kiosks, and voice-assisted chat on mobile devices.
  • Founded by Vinay Shukla and Rahul Aggarwal in 2018, ConverseNow is headquartered in Austin, Texas.

Artio Medical Appoints Abhinav Shukla to Board of Directors

Retrieved on: 
Thursday, June 24, 2021

PRAIRIE VILLAGE, Kan., June 24, 2021 /PRNewswire/ -- Artio Medical, Inc. , a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announces the appointment of Abhinav Shukla to the company's Board of Directors.

Key Points: 
  • PRAIRIE VILLAGE, Kan., June 24, 2021 /PRNewswire/ -- Artio Medical, Inc. , a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announces the appointment of Abhinav Shukla to the company's Board of Directors.
  • Prior to his Board appointment, Shukla served as a major investor and strategic advisor to the company.
  • "Artio Medical has an impressive and highly differentiated product portfolio that aims to address important unmet medical needs across several large, attractive markets," said Shukla.
  • "We are thrilled to have Abhinav join the Artio board and deepen his relationship with the company," commented F. Nicholas Franano, MD, President and CEO of Artio Medical.

Actor Ed Asner, Inventor Nolan Bushnell, TED Founder Richard Saul Wurman, Silicon Valley Entrepreneur Anu Shukla Interviewed at What's Next Longevity Venture Summit

Retrieved on: 
Tuesday, June 15, 2021

The online learning event focuses on investment trends for an aging society and opportunities to develop business partnerships.

Key Points: 
  • The online learning event focuses on investment trends for an aging society and opportunities to develop business partnerships.
  • In the "Luminary Interviews: Listen and Learn" session Mary Furlong, founder of MFA, interviews serial entrepreneur, Anu Shukla, who has more than 25 years of high-tech industry experience.
  • Richard Saul Wurman, the 86-year-old architect of information and founder of the TED Conference, is interviewed by Ted Fischer, founder and CEO of Ageless Innovation.
  • Each year the What's Next Longevity Venture Summit focuses on who is investing and what the priorities are in the $8.3 trillion longevity market.

Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer

Retrieved on: 
Tuesday, June 1, 2021

AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer.
  • This is an incredibly exciting time to join Shattuck, said Dr. Shukla, Ph.D. With two clinical-stage ARC compounds and two novel protein engineering platforms, Shattuck is uniquely positioned to expand the therapeutic application of bi-functional fusion proteins.
  • I am particularly excited to work with the executive team to further the development of both ARC and GADLEN compounds.
  • Dr. Shukla joins Shattuck from Redpin Therapeutics, where he was the Chief Technical Operations Officer and was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing.

MediaMath Bolsters Leadership Team with Appointment of Industry Veterans Ingrid Hackett as General Counsel, Ashish Shukla as Chief Technology Officer and Laurent Cordier as Chief Partnerships Officer

Retrieved on: 
Wednesday, April 14, 2021

MediaMath welcomes Ingrid Hackett as General Counsel, Ashish Shukla as Chief Technology Officer and Laurent Cordier as Chief Partnerships Officer.\n"I am thrilled to welcome Ingrid, Ashish and Laurent to our leadership team.

Key Points: 
  • MediaMath welcomes Ingrid Hackett as General Counsel, Ashish Shukla as Chief Technology Officer and Laurent Cordier as Chief Partnerships Officer.\n"I am thrilled to welcome Ingrid, Ashish and Laurent to our leadership team.
  • As General Counsel for MediaMath, she will provide guidance to management and the senior leadership team to help the company navigate the constantly evolving regulatory and privacy environment.
  • She will partner with the leadership team to determine the right strategic outcomes for MediaMath and build out legal processes supporting our growth.
  • MediaMath has a clear vision for the future of the digital advertising industry that is rooted in accountability and transparency," said Ingrid Hackett, General Counsel, MediaMath.

Biopharmaceutical Industry Leader Abhinav Shukla Joins Redpin Therapeutics as Chief Technical Operations Officer

Retrieved on: 
Tuesday, March 31, 2020

Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the appointment of Abhinav A. Shukla, PhD, as its Chief Technical Operations Officer (CTOO).

Key Points: 
  • Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the appointment of Abhinav A. Shukla, PhD, as its Chief Technical Operations Officer (CTOO).
  • Dr. Shukla joins Redpin with a strong reputation as a leader and innovator in the biopharmaceutical process development and manufacturing space.
  • Throughout his career Dr. Shukla has been involved in >75 INDs and in the commercialization of Orencia, Yervoy, Nulojix and Xgeva amongst other therapeutics.
  • I am delighted to join Redpin at this critical inflection point for the company, said Dr. Abhinav Shukla, Chief Technical Operations Officer of Redpin.

Aspen Dental Management, Inc. Announces Abhinav Shukla as Chief Operating Officer

Retrieved on: 
Monday, April 8, 2019

Aspen Dental Management, Inc. (ADMI), one of the largest and fastest-growing dental support organizations (DSO) in the U.S., announced today that Abhinav Shukla is joining the company as chief operating officer (COO).

Key Points: 
  • Aspen Dental Management, Inc. (ADMI), one of the largest and fastest-growing dental support organizations (DSO) in the U.S., announced today that Abhinav Shukla is joining the company as chief operating officer (COO).
  • Ive been impressed by the expertise and perspective that Abhinav brings to the table, and cant wait to see the impact hell have on the Aspen Dental brand.
  • Added Shukla, Im excited to bring my experience in building and leading teams in retail and consumer focused businesses to the dentists who own and operate Aspen Dental branded practices.
  • For additional information about Aspen Dental or to find an Aspen Dental office, please visit www.aspendental.com .